Brean Capital Initiates Sorrento Therapeutics At Buy

Analysts at Brean Capital initiated coverage on

with a Buy rating. The target price for Sorrento Therapeutics is set to $17. Sorrento Therapeutics shares have gained 156.19 percent over the past 52 weeks, while the S&P 500 index has surged 10.60 percent in the same period. Sorrento Therapeutics' shares fell 1.46 percent to $12.85 in after-hours trading.